A detailed history of Nomura Holdings Inc transactions in United Therapeutics Corp stock. As of the latest transaction made, Nomura Holdings Inc holds 4,052 shares of UTHR stock, worth $1.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,052
Previous 3,307 22.53%
Holding current value
$1.89 Million
Previous $950,000 78.74%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$274.7 - $438.75 $204,651 - $326,868
745 Added 22.53%
4,052 $1.7 Million
Q2 2025

Aug 18, 2025

SELL
$276.47 - $328.4 $276 - $328
-1 Reduced 0.03%
3,307 $950,000
Q2 2025

Aug 14, 2025

SELL
$276.47 - $328.4 $283,381 - $336,610
-1,025 Reduced 23.66%
3,308 $950,000
Q1 2025

May 15, 2025

SELL
$304.42 - $380.78 $484,332 - $605,820
-1,591 Reduced 26.86%
4,333 $1.34 Million
Q4 2024

Feb 14, 2025

BUY
$348.66 - $410.0 $2.07 Million - $2.43 Million
5,924 New
5,924 $2.09 Million
Q2 2024

Aug 14, 2024

BUY
$228.26 - $319.04 $180,781 - $252,679
792 New
792 $252,000
Q2 2021

Aug 16, 2021

SELL
$170.47 - $211.93 $1.07 Million - $1.32 Million
-6,250 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$153.94 - $174.85 $962,125 - $1.09 Million
6,250 New
6,250 $1.05 Million
Q4 2018

Feb 14, 2019

SELL
$101.4 - $128.73 $164,775 - $209,186
-1,625 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$113.81 - $129.46 $396,058 - $450,520
-3,480 Reduced 68.17%
1,625 $205,000
Q2 2018

Aug 14, 2018

SELL
$101.14 - $118.31 $659,028 - $770,907
-6,516 Reduced 56.07%
5,105 $537,000
Q4 2017

Feb 14, 2018

BUY
$118.58 - $151.28 $568,116 - $724,782
4,791 Added 70.15%
11,621 $1.72 Million
Q3 2017

Nov 14, 2017

BUY
$114.6 - $136.81 $782,718 - $934,412
6,830
6,830 $802,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $21.2B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Nomura Holdings Inc Portfolio

Follow Nomura Holdings Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Holdings Inc with notifications on news.